GLP-1 medicines copy a gut hormone that curbs appetite, and they do more for weight and metabolic health than any drug before them.
The basics still do the foundational work:
- whole food
- steady activity
- sleep
- enough protein
In large randomized trials semaglutide produced about 15% weight loss and tirzepatide about a fifth. Both lowered long-term blood sugar by around two percentage points in type 2 diabetes. Semaglutide also cut major cardiovascular events about a fifth in people who were overweight with heart disease and no diabetes.
They carry trade-offs: gut side effects common early, some muscle lost along with the fat, and weight that returns when the drug stops. They are prescription medicines, and whether one fits is a decision made with a prescriber.
Findings & Outcomes
What It Is
GLP-1 medicines are engineered copies of a gut hormone the body releases after eating, one that curbs appetite. The best known is semaglutide, sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for weight management. Tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight, acts on two gut-hormone receptors at once. Most are given as a weekly injection, and an oral form exists. They began as diabetes treatments and turned out to produce weight loss and heart protection well beyond earlier diabetes drugs.
These drugs act on the biology of appetite. Hunger and fullness are controlled by hormones. In many people these hold body weight around a higher set point, making weight hard to lose and easy to regain. Much of that pressure is manufactured. Ultra-processed foods engineered around fat, sugar, and salt supply more than half of the calories in the average American adult's diet. That food environment is a driver of the weight these drugs treat. The GLP-1 drugs act on the appetite system directly. That is why they produce weight loss diet and exercise alone rarely reach.
What It Does
The largest and most certain effect is weight. In large randomized trials semaglutide takes off about 15% of body weight, tirzepatide closer to a fifth, more than any drug before them. In type 2 diabetes they also lower long-term blood sugar (HbA1c) by around two percentage points.
Over years, in people with diabetes or established heart disease, these drugs prevent major cardiovascular events, slow kidney disease, and lower the chance of dying from any cause. Semaglutide cut major cardiovascular events by about a fifth in people who were overweight and had heart disease but no diabetes. It was the first GLP-1 drug shown to do so without diabetes in the picture.
At the approved weekly dose, semaglutide now improves both the inflammation and the early scarring of metabolic (MASH) liver disease. Trials are extending into obstructive sleep apnea and other conditions.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
Weight And Fat Loss
Semaglutide took off about 15% of body weight in obesity
People with obesity lost about 15% of their body weight over roughly sixteen months on weekly semaglutide, compared with about 2% on a dummy injection, and most lost at least 5%.
STEP 1 was a 68-week randomized, double-blind trial in 1,961 adults with a BMI of 30 or more (or 27 with a weight-related condition) and no diabetes, both arms receiving lifestyle counseling. Mean change in body weight was -14.9% with semaglutide 2.4 mg weekly versus -2.4% with placebo, a treatment difference of 12.4 percentage points. 86.4% of the semaglutide group lost at least 5% of body weight, 69.1% lost at least 10%, and 50.5% lost at least 15%. Weight fell steadily over the titration period and then plateaued.
The study · 1
Wilding et al., once-weekly semaglutide in adults with overweight or obesity (STEP 1) · N Engl J Med 2021;384:989-1002
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
Tirzepatide took off up to 20.9% of body weight at its top dose
On the highest dose of tirzepatide, people with obesity lost about a fifth of their body weight over eighteen months, more than the roughly 15% seen with semaglutide.
SURMOUNT-1 was a 72-week randomized, double-blind trial in 2,539 adults with obesity (or overweight with a complication) and no diabetes. Mean weight change was -15.0%, -19.5% and -20.9% at tirzepatide 5, 10 and 15 mg weekly versus -3.1% on placebo. Tirzepatide is a dual agonist acting on both the GLP-1 and the GIP receptor, and 57% of those on the 15 mg dose (50% at 10 mg) lost at least a fifth of their body weight.
The study · 1
Jastreboff et al., tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) · N Engl J Med 2022;387:205-216
About two-thirds of the lost weight returns within a year of stopping
After stopping semaglutide, people put back about two-thirds of the weight they had lost within a year, and their blood pressure and blood sugar drifted back toward where they started.
This extension followed 327 participants from STEP 1 for one year after both semaglutide and lifestyle intervention were withdrawn at week 68. Participants regained about two-thirds (11.6 percentage points of the 17.3% lost) of their prior weight loss by week 120, and cardiometabolic improvements including blood pressure and glycated hemoglobin similarly reverted toward baseline. The pattern reflects that the drug acts only while it is taken and does not reset the body's set point.
Because the effect depends on staying on the drug, plan from the outset for the long term, including cost and the habits that support the result.
The study · 1
Wilding et al., weight regain and cardiometabolic effects after withdrawal of semaglutide, the STEP 1 trial extension · Diabetes Obes Metab 2022;24:1553-1564
Blood Sugar
Both drugs cut HbA1c about 2 percentage points in type 2 diabetes
In type 2 diabetes, both drugs lowered long-term blood sugar (HbA1c) by around two percentage points, a large drop, with tirzepatide slightly ahead of semaglutide.
SURPASS-2 was a 40-week open-label randomized trial in 1,879 adults with type 2 diabetes inadequately controlled on metformin (mean baseline HbA1c 8.28%). HbA1c fell by 2.01, 2.24 and 2.30 percentage points on tirzepatide 5, 10 and 15 mg and by 1.86 on semaglutide 1 mg. Tirzepatide was non-inferior and superior to semaglutide at all three doses, and produced greater weight loss as well.
The study · 1
Frias et al., tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2) · N Engl J Med 2021;385:503-515
Heart And Vascular
Semaglutide cut major cardiovascular events 20% in obesity without diabetes
In people who were overweight and already had heart disease but not diabetes, semaglutide lowered the rate of heart attacks, strokes and cardiovascular deaths by about a fifth over three years.
SELECT was a randomized, double-blind trial in 17,604 adults aged 45 or over who were overweight or obese and had established cardiovascular disease but not diabetes. Over a mean follow-up of 39.8 months, the primary composite endpoint occurred in 6.5% on semaglutide 2.4 mg versus 8.0% on placebo (HR 0.80, 95% CI 0.72 to 0.90). This was the first trial to show a GLP-1 drug prevents cardiovascular events in people without diabetes, and the benefit appeared partly separable from the weight lost.
The study · 1
Lincoff et al., semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT) · N Engl J Med 2023;389:2221-2232
Semaglutide cut major cardiovascular events 26% in high-risk type 2 diabetes
In people with type 2 diabetes at high heart risk, semaglutide lowered heart attacks, strokes and cardiovascular deaths by about a quarter over two years.
SUSTAIN-6 was a 104-week randomized, double-blind pre-approval cardiovascular safety trial in 3,297 adults with type 2 diabetes at high cardiovascular risk. The primary composite occurred in 6.6% on semaglutide versus 8.9% on placebo (HR 0.74, 95% CI 0.58 to 0.95), driven mainly by a reduction in nonfatal stroke and nonfatal heart attack, not cardiovascular death.
The study · 1
Marso et al., semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6) · N Engl J Med 2016;375:1834-1844
Longevity And Mortality
GLP-1 drugs lowered death from any cause 12% in type 2 diabetes
Pooling the big diabetes heart-outcome trials, these drugs lowered the chance of dying from any cause by about 12%, and cut heart and kidney events as well.
This systematic review and meta-analysis pooled 8 randomized cardiovascular-outcome trials of GLP-1 receptor agonists in 60,080 adults with type 2 diabetes. All-cause mortality was reduced by 12% (HR 0.88, 95% CI 0.82 to 0.94), the three-point major adverse cardiovascular event composite by 14% (HR 0.86), and a composite kidney outcome by 21% (HR 0.79). Effects were broadly consistent across the individual drugs in the class.
The study · 1
Sattar et al., cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in type 2 diabetes, systematic review and meta-analysis · Lancet Diabetes Endocrinol 2021;9:653-662
Digestion
Nausea reached about 44% early on, and about 7% stopped the drug
Nausea is the most common side effect, reaching nearly half of people early on, along with diarrhea, vomiting and constipation. They are usually mild to moderate and fade as the body adjusts, though some people stop because of them.
In the STEP 1 obesity trial (1,961 adults, 68 weeks), gastrointestinal disorders were the most frequent adverse events with semaglutide 2.4 mg: nausea in about 44% versus 18% on placebo, with diarrhea, vomiting and constipation also raised. Most events were transient and mild to moderate, concentrated in the dose-escalation period. Discontinuation for adverse events was about 7% on semaglutide versus 3% on placebo, driven largely by gastrointestinal symptoms.
Raising the dose slowly, eating smaller meals, and stopping when full reduce the symptoms; severe or lasting symptoms are a reason to have the prescriber slow the pace or pause.
The study · 1
Wilding et al., once-weekly semaglutide in adults with overweight or obesity (STEP 1), adverse events · N Engl J Med 2021;384:989-1002
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
Semaglutide 2.4 mg improved liver fibrosis in 36.8% versus 22.4% and resolved steatohepatitis in 62.9% versus 34.3%
In people with the inflammatory form of fatty liver disease and early scarring, semaglutide at the approved 2.4 mg weekly dose cleared the inflammation in about 63% versus 34% on placebo and improved the scarring in 36.8% versus 22.4%. An earlier trial at a lower daily dose had cleared the inflammation but not moved the scarring.
The phase 3 ESSENCE trial randomized 1,197 adults with biopsy-defined metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis stage F2 or F3 in a 2:1 ratio to once-weekly semaglutide 2.4 mg or placebo. At the prespecified week-72 interim analysis of the first 800 patients, reduction in liver fibrosis without worsening of steatohepatitis occurred in 36.8% on semaglutide versus 22.4% on placebo, and resolution of steatohepatitis without worsening of fibrosis in 62.9% versus 34.3%, both P<0.001; 32.7% achieved both. An earlier 72-week phase 2 trial in 320 adults, using a lower daily 0.4 mg dose, had resolved steatohepatitis in 59% versus 17% but had not significantly improved the fibrosis stage.
At the approved weekly dose, semaglutide now improves both the inflammation and the early scarring of MASH, so the liver benefit is one reason it may be considered when MASH occurs alongside obesity or type 2 diabetes, guided by a specialist. Whether it prevents cirrhosis and its complications is still being tested.
The studies · 2
Semaglutide in MASH with fibrosis, ESSENCE, NEJM 2025 · N Engl J Med 2025
Newsome et al., a placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis · N Engl J Med 2021;384:1113-1124
Kidney Disease
Semaglutide cut major kidney events 24% in diabetic kidney disease
In people with type 2 diabetes and existing kidney disease, semaglutide cut the chance of kidney failure and major kidney decline by about a quarter.
FLOW was a randomized, double-blind trial in 3,533 adults with type 2 diabetes and chronic kidney disease. The primary composite of major kidney disease events (onset of kidney failure, a sustained fall in eGFR of at least 50%, or death from kidney or cardiovascular causes) was reduced by 24% with semaglutide (HR 0.76, 95% CI 0.66 to 0.88). The trial was stopped early for efficacy, and semaglutide also reduced cardiovascular events and death from any cause.
The study · 1
Perkovic et al., effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW) · N Engl J Med 2024;391:109-121
Muscle And Strength
About a quarter of the weight lost is muscle, not fat
About a quarter of the weight lost on these drugs is muscle and other lean tissue, not fat, similar to weight loss by other means. The body did not become proportionally less muscular, so the concern is the total muscle lost, which counts more as you age.
This meta-analysis pooled 22 randomized trials (2,258 participants) with body-composition measurement. GLP-1 receptor agonists reduced total body weight by about 7.8 lb (3.55 kg), with lean mass accounting for approximately 25% of the loss. Relative lean mass, expressed as percent change from baseline, was unaffected, indicating the body did not become proportionally less muscular. Liraglutide was the only agent to reduce weight without significantly cutting lean mass, while semaglutide and tirzepatide were the most effective for fat loss and among the least effective at preserving lean mass.
Enough protein and regular resistance training are the levers shown to protect muscle during weight loss, which is why they belong alongside the drug, not after it, especially for older adults.
The study · 1
Effect of GLP-1 receptor agonists and co-agonists on body composition, network meta-analysis · Metabolism 2025
How It Works
These drugs work on three linked systems at once. In the brain, they act on appetite centers to reduce hunger and the urge to eat between meals. In the stomach, they slow how fast a meal empties, so fullness comes sooner and lasts longer and the rise in blood sugar after eating is gentler. In the pancreas, they raise insulin release only when blood sugar is high. That is why, used alone, they rarely push it too low. For the metabolic system underneath all of this, see insulin and glucose handling.
Anatomy of the Practice
1The gut hormone they copy
The gut releases GLP-1 after eating, then breaks it down within minutes. These drugs copy that hormone in a form that resists breakdown, so a single weekly injection keeps the signal going for days. Because they are proteins, they break down if swallowed, so most are injected. The dose is raised in steps over several weeks to let the gut adjust.
2The two-receptor drugs
Tirzepatide adds a second target, the GIP receptor, alongside GLP-1. GIP, another gut hormone, helps drive insulin release and fat storage. Acting on both receptors appears to produce more weight loss than GLP-1 alone. That is the leading explanation for tirzepatide's larger effect.
3Why appetite falls
In trials that measured energy use, the weight loss comes almost entirely from eating less, with little change in how many calories the body burns. Slower stomach emptying means food stays longer and fullness comes sooner. Brain signaling lowers hunger and the urge to eat between meals. Less food goes in, and the body draws on its own fat stores.
The Trade-offs and What Is Not Yet Known
Gut side effects are the most common cost of these drugs. Raising the dose slowly is the main lever that keeps them manageable, though a minority stop the drug because of them.
Some of the loss is lean muscle, and older adults start with less to spare, so how much you lose matters more with age. Enough protein and regular resistance training are the two levers shown to protect it: see protein and muscle and resistance training.
The effect lasts only while the drug is taken. The weight and the metabolic gains return when the drug stops, so these are treatment for an ongoing condition, planned over years.
Some things are not settled. The longest trials run about three to four years, so the open questions are all about the long run:
- Decade-scale safety is not yet established.
- Most of the weight and heart evidence comes from people who were obese or already at high cardiovascular risk, so the benefit in lower-risk, general use is less certain.
Using Them Well
Starting a GLP-1 drug is a decision to make with a prescriber. What to bring to that conversation, and how to get the most from the treatment if it fits:
Whole food, steady activity, sleep, and enough protein are the foundation of weight and metabolic health. The drug builds on these habits, and they stay whether or not you go on the medicine. Keep them from the start.
Whether one fits depends on your weight, your blood sugar, your heart and kidney health, and your other conditions and medicines. A clinician sets the starting dose, raises it in steps, and monitors how you respond.
Raising the dose slowly is what keeps gut symptoms manageable. Eating smaller meals, slowing down, and stopping when full tend to help. If symptoms are severe or lasting, the prescriber can slow the pace or pause the increase.
Think from the outset about the plan over years, and the eating and training habits that support the result whether or not you stay on the drug.
Go Deeper
- Type 2 diabetes: where these drugs change long-term outcomes, next to the lifestyle levers that matter most in early disease.
- Weight and metabolic health: the whole picture of fat loss, where these drugs sit after the basics of training, protein and whole food.
- Peptides: the wider peptide market, where the GLP-1 drugs are the approved, trial-tested end.
- Protein and muscle: the daily protein target that preserves lean mass while you lose fat.
- Resistance training: the minimum effective dose of resistance work, and why it holds muscle during weight loss.
The Chinese Medicine View
These are modern drugs, isolated and engineered in the last few decades, so there is no classical Chinese entry for any of them. No historical text assigns a channel, a temperature or a flavor to a GLP-1 medicine, and no traditional formula contains one.
These drugs act on functions Chinese medicine has always reasoned about. The Spleen, in this framework, governs the transformation and transport of food into usable substance. The Spleen and Stomach are the two organs it reads as the seat of appetite, fullness and digestion. When that function is weak, the tradition describes food and fluid failing to move and transform, gathering instead as Dampness and Phlegm. Those patterns are often laid over the modern picture of carrying excess weight with a sluggish metabolism. A drug that slows the stomach, reduces appetite and shifts how the body handles food is, in a loose sense, acting on those same functions.
The tradition would also draw a distinction. The drug reduces appetite. It does not, in this framework, strengthen the Spleen function itself. Chinese medicine reads three signs (persistent poor appetite, early fullness and fatigue after eating) as a depleted Spleen. In this framework those signs are a depletion to correct. So the drug addresses the symptom, appetite, while the tradition's own aim, a Spleen that transforms food well on its own, is left untouched. That gap is one reading of why the effect fades once the drug is stopped.
Cautions For These Medications
Everything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.
GLP-1 drugs raised gallbladder and biliary disease about a third
This systematic review and meta-analysis pooled 76 randomized trials (103,371 patients, mean age 57.8, 40.5% women). Randomization to a GLP-1 receptor agonist was associated with a 37% higher risk of gallbladder or biliary disease (RR 1.37, 95% CI 1.23 to 1.52), including cholelithiasis (RR 1.27) and cholecystitis (RR 1.36). Risk was higher at higher doses (RR 1.56) and with longer treatment, and was greatest in weight-loss trials (RR 2.29) versus diabetes trials (RR 1.27), consistent with rapid weight loss being part of the mechanism. The trials reported relative risks without a clean absolute figure.He et al., association of GLP-1 receptor agonist use with risk of gallbladder and biliary diseases, systematic review and meta-analysis of randomized clinical trials
These are prescription medicines, and the starting decision sits with a clinician
Whether one fits, at what dose, and how fast to raise it depends on your full picture: blood sugar, heart and kidney health, other conditions and other medicines. Start, change, or stop one only with your prescriber. Compounded or gray-market versions sold outside a pharmacy carry no check on what is actually in the vial, and dosing errors with them have sent people to the hospital.
Not in pregnancy or when trying to conceive
These drugs are not recommended in pregnancy, and guidance is to stop them well before a planned pregnancy because they clear slowly. Anyone who could become pregnant should discuss contraception and timing with a prescriber. Because early appetite suppression can reduce how well the pill is absorbed, a backup method is often advised. Rapid weight loss around conception is itself a reason for medical guidance.
Gallbladder, biliary and pancreas
Across randomized trials these drugs raise the risk of gallbladder and biliary disease by about a third. The risk is higher at larger doses and in weight-loss use, partly a consequence of rapid weight loss itself. Pancreatitis has been reported as well. Severe, persistent abdominal pain, especially with vomiting, is a reason to seek care promptly; do not wait it out.
A thyroid contraindication for some families
In rodent studies these drugs caused thyroid C-cell tumors. It has not been shown in people. Still, the drugs are contraindicated for anyone with a personal or family history of medullary thyroid carcinoma, or the genetic syndrome MEN 2. Raise that history before starting.
Severe or lasting gut symptoms
Nausea, vomiting, diarrhea and constipation are the usual side effects and are most common in the first weeks and while the dose climbs. For most people they are mild to moderate and ease with time and a slower increase. If they are severe or lead to dehydration, the prescriber should adjust the plan.
Tell your team before surgery or an endoscopy
Because these drugs slow how fast the stomach empties, food can remain longer than expected. That raises the risk of breathing stomach contents into the lungs under sedation or general anesthesia. Anesthesiology guidance now asks that your prescriber and procedure team know you take one. They can then hold a dose or take extra precautions before surgery or an endoscopy. Do not stop on your own, but do make sure they know.
Start slow, be smart, read the research, and consult a professional if you have any concerns. This is here to inform your choice, not make it for you.
Common Questions
How much weight do people lose on GLP-1 medicines?
Averaged across the big trials, adults with obesity lost about 15% of body weight over 16 months on weekly semaglutide, against about 2% on a dummy injection. Tirzepatide's highest dose reached about a fifth. These are averages; individual results vary widely, and the loss builds gradually as the dose climbs. Those figures come from people without diabetes, in type 2 diabetes the weight loss tends to run somewhat smaller.
Do these drugs help the heart, or only weight?
They do more than trim weight. The cardiovascular benefit (fewer heart attacks, strokes, and cardiovascular deaths over roughly three years) is larger than weight loss alone would predict. That points to effects on blood vessels and inflammation beyond the pounds lost. In type 2 diabetes, semaglutide lowered cardiovascular events as well. That combination of weight, blood-sugar, and heart benefit is why these drugs are used for more than weight loss.
What happens if I stop taking one?
In the extension of the semaglutide weight trial, people regained about two-thirds of what they had lost within a year of stopping.
Blood pressure and blood-sugar markers drifted back toward where they started. Building steady eating and training habits alongside the drug holds on to more of the result if the drug is ever stopped.
Will I lose muscle on a GLP-1 medicine?
Some. When the body loses a large amount of weight, part of it is muscle. Pooled trial data put that share at about a quarter of the total, similar to weight loss by any means. Lean mass fell in step with total weight, the share of the body that is muscle stayed about the same.
Are GLP-1 medicines a cure for type 2 diabetes?
They treat type 2 diabetes powerfully without curing it. Blood sugar falls sharply on both drugs, but it tends to rise again if the drug stops. Early type 2 diabetes can sometimes reach remission through weight loss itself. These drugs drive that weight loss but do not, on their own, make the remission permanent. They work best inside care that also uses the lifestyle levers on the type 2 diabetes page.
They are expensive. Are compounded or online versions the same thing?
Not reliably. Brand-name GLP-1 drugs are costly, and coverage varies widely. That gap has driven a large market in compounded and online versions. Those are not held to the same manufacturing checks, so what is in them is not guaranteed. If cost is the barrier, a prescriber can walk through approved brands like Wegovy or Zepbound and any access programs.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 13 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 9, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.